Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Kenneth H. Mayer, Jean‐Michel Molina, Melanie Thompson, Peter L. Anderson, Karam Mounzer, Joss J De Wet, Edwin DeJesus, Heiko Jessen, Robert M. Grant, Peter Ruane, Pamela Wong, Ramin Ebrahimi, Lijie Zhong, Anita Mathias, Christian Callebaut, Sean E Collins, Moupali Das, Scott McCallister, Diana M. Brainard, Cynthia Brinson, Amanda Clarke, Pep Coll, Frank A. Post, C. Bradley Hare
Topics & Concepts
EmtricitabineTenofovir alafenamideTenofovirMedicineHuman immunodeficiency virus (HIV)Pre-exposure prophylaxisRandomized controlled trialInternal medicineAntiretroviral therapyFamily medicineMen who have sex with menViral loadSyphilisHIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV-related health complications and treatments